OLEMA PHARMACEUTICALS, INC. Investment Income, Interest
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Investment Income, Interest of $4.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2026-06-30 was $4.51M, a 11.50% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2026-03-31 was $4.78M, a 5.57% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2025-12-31 was $4.01M, a 21.74% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2025-09-30 was $3.65M, a 24.59% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. investment income, interest for fiscal 2025 was $16.22M, a 27.93% increase from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. investment income, interest for fiscal 2024 was $12.68M, a 52.34% increase from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. investment income, interest for fiscal 2023 was $8.32M, a 273.65% increase from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. investment income, interest for fiscal 2022 was $2.23M, a 404.07% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.51M 10-Q · filed 2026-08-10 | $9.28M 10-Q · filed 2026-08-10 | $13.29M derived: sum of 3 quarters · filed 2026-08-10 | $16.94M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $4.78M 10-Q · filed 2026-05-12 | $8.79M derived: sum of 2 quarters · filed 2026-05-12 | $12.43M derived: sum of 3 quarters · filed 2026-05-12 | $16.48M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $4.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $7.66M derived: sum of 2 quarters · filed 2026-03-16 | $11.70M derived: sum of 3 quarters · filed 2026-08-10 | $16.22M 10-K · filed 2026-03-16 |
| 2025-09-30 | $3.65M 10-Q · filed 2025-11-10 | $7.69M derived: sum of 2 quarters · filed 2026-08-10 | $12.21M 10-Q · filed 2025-11-10 | $15.51M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $4.04M 10-Q · filed 2026-08-10 | $8.57M 10-Q · filed 2026-08-10 | $11.86M derived: sum of 3 quarters · filed 2026-08-10 | $14.79M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $4.52M 10-Q · filed 2026-05-12 | $7.82M derived: sum of 2 quarters · filed 2026-05-12 | $10.75M derived: sum of 3 quarters · filed 2026-05-12 | $13.85M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $3.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $6.22M derived: sum of 2 quarters · filed 2026-03-16 | $9.33M derived: sum of 3 quarters · filed 2026-03-16 | $12.68M 10-K · filed 2026-03-16 |
| 2024-09-30 | $2.93M 10-Q · filed 2025-11-10 | $6.04M derived: sum of 2 quarters · filed 2025-11-10 | $9.39M 10-Q · filed 2025-11-10 | $12.94M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $3.11M 10-Q · filed 2025-08-11 | $6.46M 10-Q · filed 2025-08-11 | $10.01M derived: sum of 3 quarters · filed 2025-08-11 | $11.93M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $3.35M 10-Q · filed 2025-05-13 | $6.90M derived: sum of 2 quarters · filed 2025-05-13 | $8.82M derived: sum of 3 quarters · filed 2025-05-13 | $10.37M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $3.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $5.47M derived: sum of 2 quarters · filed 2025-03-18 | $7.02M derived: sum of 3 quarters · filed 2025-03-18 | $8.32M 10-K · filed 2025-03-18 |
| 2023-09-30 | $1.92M 10-Q · filed 2024-11-12 | $3.47M derived: sum of 2 quarters · filed 2024-11-12 | $4.77M 10-Q · filed 2024-11-12 | $5.75M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.55M 10-Q · filed 2024-08-06 | $2.85M 10-Q · filed 2024-08-06 | $3.83M derived: sum of 3 quarters · filed 2024-08-06 | $4.45M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.30M 10-Q · filed 2024-05-08 | $2.28M derived: sum of 2 quarters · filed 2024-05-08 | $2.90M derived: sum of 3 quarters · filed 2024-05-08 | $3.31M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $973.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $1.59M derived: sum of 2 quarters · filed 2024-03-11 | $2.01M derived: sum of 3 quarters · filed 2024-03-11 | $2.23M 10-K · filed 2024-03-11 |
| 2022-09-30 | $622.00K 10-Q · filed 2023-11-07 | $1.04M derived: sum of 2 quarters · filed 2023-11-07 | $1.25M 10-Q · filed 2023-11-07 | $1.36M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $415.00K 10-Q · filed 2023-08-08 | $633.00K 10-Q · filed 2023-08-08 | $742.00K derived: sum of 3 quarters · filed 2023-08-08 | $847.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $218.00K 10-Q · filed 2023-05-09 | $327.00K derived: sum of 2 quarters · filed 2023-05-09 | $432.00K derived: sum of 3 quarters · filed 2023-05-09 | $549.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $109.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $214.00K derived: sum of 2 quarters · filed 2023-03-09 | $331.00K derived: sum of 3 quarters · filed 2023-03-09 | $442.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $105.00K 10-Q · filed 2022-11-08 | $222.00K derived: sum of 2 quarters · filed 2022-11-08 | $333.00K 10-Q · filed 2022-11-08 | $334.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $117.00K 10-Q · filed 2022-08-09 | $228.00K 10-Q · filed 2022-08-09 | $229.00K derived: sum of 3 quarters · filed 2022-08-09 | $252.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $111.00K 10-Q · filed 2022-05-09 | $112.00K derived: sum of 2 quarters · filed 2022-05-09 | $135.00K derived: sum of 3 quarters · filed 2022-05-09 | $168.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $24.00K derived: sum of 2 quarters · filed 2022-02-28 | $57.00K derived: sum of 3 quarters · filed 2022-02-28 | $60.00K 10-K · filed 2022-02-28 |
| 2020-09-30 | $23.00K 10-Q · filed 2021-11-10 | $56.00K derived: sum of 2 quarters · filed 2021-11-10 | $59.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $33.00K 10-Q · filed 2021-08-10 | $36.00K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $3.00K 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | $7.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |